CYTOTOXIC ACTIVITY OF PROBIOTIC BACILLUS SUBTILIS SK09 AGAINST HUMAN COLON CANCER CELL LINE (HT-29)

Abstract

Probiotics are provided as nutraceutical supplements to aid in proper digestion of lactose rich dairy products and act as enhancers of prophylaxis. The probiotic organism Bacillus subtilis SK09, isolated from dairy effluents, is capable of metabolizing lactose and sporulating under stressed conditions. Its metabolite analysis profile confirms that it is a novel strain, which produces anti-carcinogenic compounds such as 8-Octadecenoic acid, methyl ester; (2,7-Diphenyl-1-6dioxopyridazino(4,5:2'3') pyrrolo(4',5'-d)pyridazine; Octadec-9-enoic acid; Hexadecanoic acid, methyl ester; and 4-Piperidineaceticacid, 1-acetyl-5-ethyl-2-(3.(2.hydroxyethyl)-1H-indol-2-yl)-a-methyl, methyl ester. The present study is focused on the anti-cancerous activity of Bacillus subtilis SK09 on HT-29 cell line (Human colon cancer cell line) confirmed by 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-tetrazolium bromide (MTT) assay. The in vitro cytotoxic assay of probiotic biomass showed the significant cytotoxicity with IC50 of 7.8μg/ml. Therefore, Bacillus subtilis SK09 could be served as probiotic organism with anti-cancerous therapeutic applications.